Evidence map›Paper›PMID 31252032›Full record

Trial reportThe Journal of investigative dermatology2020

IL-4Rα Blockade by Dupilumab Decreases Staphylococcus aureus Colonization and Increases Microbial Diversity in Atopic Dermatitis.

Chris Callewaert, Teruaki Nakatsuji, Rob Knight, Tomasz Kosciolek, Alison Vrbanac, Paul Kotol, Marius Ardeleanu, Thomas Hultsch, Emma Guttman-Yassky, Robert Bissonnette and 7 more

Open access · bronzeAbstract readClinical Trial, Phase IIRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of investigative dermatology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 105 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
105citing papers in PubMed, 3 pooled it
20.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

105 citing papers in PubMed, 3 syntheses or guidelines pooled it, 208 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Correlation betweenFrontiers in immunology · 2026
    Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. [Biologics and infections: understand and recognize].Dermatologie (Heidelberg, Germany) · 2026
    Review
  13. Review
  14. Review
  15. Association betweenFrontiers in medicine · 2026
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Toward the Next Generation of In Silico Modeling of Dynamic Host-Microbiota Interactions in the Skin.JID innovations : skin science from molecules to population health · 2025
    Review

45 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

17 authors at 9 institutions in 3 countries.

Chris CallewaertDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA; Center for Microbial Ecology and Technology, Ghent University, Ghent, Belgium.
Teruaki NakatsujiDepartment of Dermatology, University of California San Diego, La Jolla, California, USA.
Rob KnightDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA; Departments of Computer Science and Engineering, University of California San Diego, La Jolla, California, USA; Center for Microbiome Innovation, University of California San Diego, La Jolla, California, USA.
Tomasz KosciolekDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Alison VrbanacDepartment of Pediatrics, University of California San Diego, La Jolla, California, USA.
Paul KotolDepartment of Dermatology, University of California San Diego, La Jolla, California, USA.
Marius ArdeleanuRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Thomas HultschSanofi-Genzyme, Cambridge, Massachusetts, USA.
Emma Guttman-YasskyDepartment of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Robert BissonnetteInnovaderm Research, Inc., Montreal, Quebec, Canada.
Jonathan I SilverbergDepartments of Dermatology, Preventive Medicine, and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
James KruegerLaboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
Alan MenterDepartment of Dermatology, Baylor University Medical Center, Dallas, Texas, USA.
Neil M H GrahamRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Gianluca PirozziSanofi, Bridgewater, New Jersey, USA.
Jennifer D HamiltonRegeneron Pharmaceuticals, Inc., Tarrytown, New York, USA.
Richard L GalloDepartment of Dermatology, University of California San Diego, La Jolla, California, USA. Electronic address: rgallo@ucsd.edu.
University of California San Diego · USRegeneron (United States) · USSanofi (United States) · USBaylor University Medical Center · USGhent University · BEIcahn School of Medicine at Mount Sinai · USInnovaderm (Canada) · CANorthwestern University · USRockefeller University · US

Funding

Conflict and Cooperation between AMP Species on the skinR01AR076082 · NIAMS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GALLO, RICHARD L, NAKATSUJI, TERUAKI · 2019 to 2023
$2.3M
NIAMS NIH HHS R01 AR076082
6 · The paper itself

Abstract

Dupilumab is a fully human antibody to interleukin-4 receptor α that improves the signs and symptoms of moderate to severe atopic dermatitis (AD). To determine the effects of dupilumab on Staphylococcus aureus colonization and microbial diversity on the skin, bacterial DNA was analyzed from swabs collected from lesional and nonlesional skin in a double-blind, placebo-controlled study of 54 patients with moderate to severe AD randomized (1:1) and treated with either dupilumab (200 mg weekly) or placebo for 16 weeks. Microbial diversity and relative abundance of Staphylococcus were assessed by DNA sequencing of 16S ribosomal RNA, and absolute S. aureus abundance was measured by quantitative PCR. Before treatment, lesional skin had lower microbial diversity and higher overall abundance of S. aureus than nonlesional skin. During dupilumab treatment, microbial diversity increased and the abundance of S. aureus decreased. Pronounced changes were seen in nonlesional and lesional skin. Decreased S. aureus abundance during dupilumab treatment correlated with clinical improvement of AD and biomarkers of type 2 immunity. We conclude that clinical improvement of AD that is mediated by interleukin-4 receptor α inhibition and the subsequent suppression of type 2 inflammation is correlated with increased microbial diversity and reduced abundance of S. aureus.

Indexed as

Antibodies, Monoclonal, HumanizedCytokinesDermatitis, AtopicDisease ProgressionDouble-Blind MethodFemaleFollow-Up StudiesHumansImmunotherapyMalePlacebosReceptors, Interleukin-4RNA, Ribosomal, 16SSkinStaphylococcal InfectionsStaphylococcus aureusAntibodies, Monoclonal, HumanizedCytokinesdupilumabPlacebosReceptors, Interleukin-4RNA, Ribosomal, 16S

Identifiers

PMID31252032
PMCPMC7163930
OpenAlexW2954068720

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.